All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Sparsentan. Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, Treatment of focal segmental glomerulosclerosis, Treatment of IgA nephropathy

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F20%3A10410629" target="_blank" >RIV/00216208:11110/20:10410629 - isvavai.cz</a>

  • Alternative codes found

    RIV/00064165:_____/20:10410629

  • Result on the web

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=VBXPncHaI-" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=VBXPncHaI-</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1358/dof.2020.45.2.3058863" target="_blank" >10.1358/dof.2020.45.2.3058863</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Sparsentan. Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, Treatment of focal segmental glomerulosclerosis, Treatment of IgA nephropathy

  • Original language description

    Treatment of glomerular diseases remains challenging. There are limited therapeutic options currently available for focal segmental glomerulosclerosis (FSGS) and immunoglobulin A nephropathy (IgAN) and they are generally ineffective in a substantial proportion of patients who progress to end-stage kidney disease during long-term follow-up. Standard management involving renin-angiotensin-aldosterone system (RAAS) inhibitors, corticosteroids and various immunosuppressive therapies does not always achieve sustained, complete or partial remission for most patients while causing serious or intolerable adverse effects. There is a substantial unmet need for new treatments to improve outcomes. Sparsentan, a first-in-class, orally active compound combining angiotensin II type 1 (AT1) receptor blockade with endothelin ETA receptor antagonism, offers an innovative dual mechanism of action approach to the treatment of these diseases with a potentially greater nephroprotective effect, compared to RAAS or endothelin inhibition alone. We summarize the molecular and pharmacological features of sparsentan and discuss ongoing clinical trials in FSGS and IgAN. These trials were designed to examine the long-term antiproteinuric effect, nephroprotective potential and safety profile of sparsentan. We also highlight new efforts to evaluate sparsentan in the treatment of Alport syndrome. This review aims to elucidate the potential role of this novel agent in the management of glomerular diseases.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30217 - Urology and nephrology

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2020

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Drugs of the Future

  • ISSN

    0377-8282

  • e-ISSN

  • Volume of the periodical

    45

  • Issue of the periodical within the volume

    2

  • Country of publishing house

    ES - SPAIN

  • Number of pages

    20

  • Pages from-to

    79-98

  • UT code for WoS article

    000518209600001

  • EID of the result in the Scopus database

    2-s2.0-85085623463